Breaking News, Collaborations & Alliances

Biogen, Sangamo Enter Global Development Pact

To develop therapeutics for hemoglobinopathies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Idec and Sangamo BioSciences have entered an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, inherited conditions resulting abnormal structure or underproduction of hemoglobin. Biogen will employ its expertise in non-malignant hematology by leveraging Sangamo’s zinc finger nuclease (ZFN) genome-editing technology platform to develop treatments targeting sickle cell disease (SCD) and beta-thalassemia. The ZFN technology can be u...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters